# UNITED STATES
# SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

# FORM 6-K

**Report of Foreign Private Issuer**
**Pursuant to Rule 13a-16 or 15d-16**
**under the Securities Exchange Act of 1934**

**December 12, 2022**

**Commission File Number 001-35203**

# THERATECHNOLOGIES INC.
**(Translation of registrant's name into English)**

**2015 Peel Street, Suite 1100**
**Montréal, Québec, Canada**
**H3A 1T8**
**(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☐ Form 40-F ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes ☐ No ☒

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes ☐ No ☒

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_____.

**THERATECHNOLOGIES INC.**

| Exhibit | Description |
| --- | --- |
| 99.1 | Material Change Report dated December 12, 2022 |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

THERATECHNOLOGIES INC.

By: /s/ Jocelyn Lafond
Name: Jocelyn Lafond
Title: General Counsel

Date: December 12, 2022

# MATERIAL CHANGE REPORT
## Form 51-102F3

### ITEM 1 - NAME AND ADDRESS OF COMPANY

THERATECHNOLOGIES INC. (the "**Corporation**")
2015 Peel Street
11th Floor
Montréal, Québec
Canada H3A 1T8

### ITEM 2 - DATE OF MATERIAL CHANGE

December 1, 2022.

### ITEM 3 - NEWS RELEASE

A news release describing this material change was issued by the Corporation on December 1, 2022 via "GLOBE NEWSWIRE". A copy of the news release is available on the SEDAR website at www.sedar.com and on the EDGAR website at www.sec.gov/edgar as an attachment to a Form 6-K dated December 2, 2022.

### ITEM 4 - SUMMARY OF MATERIAL CHANGE

On December 1, 2022, the Corporation announced that it decided to pause the enrollment of patients in its Phase 1 clinical trial of TH1902, the Corporation's lead investigational peptide drug conjugate ("PDC") for the treatment of sortilin-expressing cancers. The Corporation also announced that it planned on submitting an amendment to its protocol to the U.S. Food and Drug Administration ("FDA") for approval.

### ITEM 5 - FULL DESCRIPTION OF MATERIAL CHANGE

On December 1, 2022, the Corporation announced that it decided to pause the enrollment of patients in its Phase 1 clinical trial of TH1902, the Corporation's lead investigational PDC for the treatment of sortilin-expressing cancers. The Corporation also announced that it planned on submitting an amendment to its protocol to the FDA for approval.

The Corporation voluntarily made the decision to pause enrollment and revisit the study design after consulting with its investigators. Efficacy results observed thus far were not convincing enough to pursue enrolling patients and did not outweigh the adverse events seen in some patients. As previously reported, these adverse events consist mainly of neuropathy and eye toxicity.

The current intent for the protocol amendment is to modify the dosage regimen to optimize the delivery of TH1902, with lower doses at more frequent intervals. The Corporation continues to investigate the results obtained thus far in the Phase 1 clinical trial.

### ITEM 6 - RELIANCE ON SUBSECTION 7.1(2) OR (3) OF NATIONAL INSTRUMENT 51-102

Not applicable.

**ITEM 7 - OMITTED INFORMATION**

Not applicable.

**ITEM 8 - EXECUTIVE OFFICER**

For further information, contact Jocelyn Lafond, General Counsel and Corporate Secretary of the Corporation at (438) 315-6607.

**ITEM 9 - DATE OF REPORT**

December 12, 2022.